Serotonin transporter 5-HTTLPR polymorphism and response to citalopram in terminally ill cancer patients: Report of twenty-one cases

Maria Anna Capozzo, Giulia Schillani, Eugenio Aguglia, Maurizio De Vanna, Luigi Grassi, Maria Anna Conte, Tullio Giraldi

Research output: Contribution to journalArticle

Abstract

The aim of this study was to examine the effects of the SSRI antidepressant drug citalopram on anxiety, depression and mental adjustment to cancer in terminally ill cancer patients, considering also the 5-HTTLPR genetic polymorphism. A group of twenty-one consecutive patients admitted to the hospice of the Casa di Cura Pineta del Carso (Trieste, Italy) with different types of advanced cancer, who were clinically judged to require treatment with an antidepressive drug, was treated with citalopram for two weeks. The response was determined and related to 5-HTTLPR. Citalopram significantly reduced the scores on the depression and anxiety subscales of the Hospital Anxiety and Depression Scale (HADS). When the effects of citalopram were analyzed in relation to the 5-HTTLPR polymorphism, the HADS depression score was significantly decreased only in patients with the "l/l" allelic variant of the serotonin transporter conferring high functional activity, while the score of the Mini-MAC fatalism scale was significantly increased in patients carrying at least one "s" allele. These preliminary findings seem to indicate that two weeks of treatment with citalopram are effective in reducing depressive symptoms in terminally ill cancer patients. Moreover, the effects of citalopram on fatalism as a strategy of mental adaptation to cancer, and on depressive symptoms depend on the allelic variants of the 5-HTTLPR genotype of the patients. These results seem to encourage the examination of a larger patient sample and of different treatment schedules, as well as a more thorough characterization of fatalism as a coping strategy in cancer patients.

Original languageEnglish
Pages (from-to)479-483
Number of pages5
JournalTumori
Volume95
Issue number4
Publication statusPublished - 2009

Keywords

  • Antidepressant drugs
  • Mental adaptation to cancer
  • Palliative care
  • Pharmacogenetics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Serotonin transporter 5-HTTLPR polymorphism and response to citalopram in terminally ill cancer patients: Report of twenty-one cases'. Together they form a unique fingerprint.

  • Cite this

    Capozzo, M. A., Schillani, G., Aguglia, E., De Vanna, M., Grassi, L., Conte, M. A., & Giraldi, T. (2009). Serotonin transporter 5-HTTLPR polymorphism and response to citalopram in terminally ill cancer patients: Report of twenty-one cases. Tumori, 95(4), 479-483.